News & Events
< Back to News Overview
Pharmaxis Signs Swiss Marketing Partner for Aridol
06 / 02 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced
today that a new distribution contract for its product, AridolT, has been signed. The
agreement, with Trimedal AG, covers the distribution and marketing of Aridol, an asthma
management tool, in Switzerland and Liechtenstein.
Trimedal AG is a specialist respiratory and allergy pharmaceutical company based in
Zurich, Switzerland. It has an extensive network of contacts with pulmonary specialists,
allergists and respiratory laboratories that will be critical for the market success of Aridol.
The five-year agreement is effective immediately, and builds on Pharmaxis' earlier clinical
and pre-registration activities for Aridol in Switzerland.
Alan Robertson, Pharmaxis chief executive officer said: This is our second marketing and
distribution agreement for Aridol, and follows an earlier announcement regarding
Scandinavia. Trimedal has valuable experience in the markets where Aridol will be sold
and distributes a complementary product range. Their respiratory franchise, market
strength and the resources they will commit to Aridol were the prime factors in selecting
them as a partner.'
Urs Amstutz, Trimedal Managing Director said: Switzerland is home to one of the research
groups which have championed the use of Aridol through multiple clinical studies. Aridol is
an exciting innovation in asthma management and the awareness of the product is already
high amongst Swiss respiratory specialists. Aridol represents a significant commercial
opportunity for Trimedal and we are looking forward to making it a success for both
Trimedal and Pharmaxis.'
Pharmaxis lodged its application for regulatory and marketing approval of Aridol with the
Swedish Medical Products Agency (MPA) in May 2005, and anticipates registration for
Aridol during the first half of 2006. Aridol is designed to identify patients with active airway
inflammation such as occurs in asthma, provide information on the severity of their disease,
and help monitor the effectiveness of their current treatment. Asthma is a widespread and
chronic condition which has a major impact on public health. In Switzerland, 7 per cent of
adults and 10 per cent of children (about 1 million) have clinical symptoms of asthma, and
the trend is increasing.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au
SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson - Pharmaxis Chief Executive Officer Ph: +61 2 9454 7202,
Fax +61 2 9451 3622
today that a new distribution contract for its product, AridolT, has been signed. The
agreement, with Trimedal AG, covers the distribution and marketing of Aridol, an asthma
management tool, in Switzerland and Liechtenstein.
Trimedal AG is a specialist respiratory and allergy pharmaceutical company based in
Zurich, Switzerland. It has an extensive network of contacts with pulmonary specialists,
allergists and respiratory laboratories that will be critical for the market success of Aridol.
The five-year agreement is effective immediately, and builds on Pharmaxis' earlier clinical
and pre-registration activities for Aridol in Switzerland.
Alan Robertson, Pharmaxis chief executive officer said: This is our second marketing and
distribution agreement for Aridol, and follows an earlier announcement regarding
Scandinavia. Trimedal has valuable experience in the markets where Aridol will be sold
and distributes a complementary product range. Their respiratory franchise, market
strength and the resources they will commit to Aridol were the prime factors in selecting
them as a partner.'
Urs Amstutz, Trimedal Managing Director said: Switzerland is home to one of the research
groups which have championed the use of Aridol through multiple clinical studies. Aridol is
an exciting innovation in asthma management and the awareness of the product is already
high amongst Swiss respiratory specialists. Aridol represents a significant commercial
opportunity for Trimedal and we are looking forward to making it a success for both
Trimedal and Pharmaxis.'
Pharmaxis lodged its application for regulatory and marketing approval of Aridol with the
Swedish Medical Products Agency (MPA) in May 2005, and anticipates registration for
Aridol during the first half of 2006. Aridol is designed to identify patients with active airway
inflammation such as occurs in asthma, provide information on the severity of their disease,
and help monitor the effectiveness of their current treatment. Asthma is a widespread and
chronic condition which has a major impact on public health. In Switzerland, 7 per cent of
adults and 10 per cent of children (about 1 million) have clinical symptoms of asthma, and
the trend is increasing.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au
SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson - Pharmaxis Chief Executive Officer Ph: +61 2 9454 7202,
Fax +61 2 9451 3622